Skip to main content
SpringerLink
Log in

Mitomycin-C in the treatment of metastatic prostate cancer: report on an EORTC phase II study

  • Published:
World Journal of Urology Aims and scope Submit manuscript

Summary

In a phase II chemotherapy study, patients with metastatic prostate cancer were given mitomycin-C 15 mg/m2 i.v. q 6 weeks. A partial response rate of 29% was demonstrated in 31 fully evaluable patients with bidimensionally measurable metastatic deposits. Within the maximum cumulative dose limit of 2 mg/kg, toxicity was low. In this dose schedule, which is convenient for the patient, mitomycin-C shows good anti-tumour activity in metastatic prostate cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Baker LH, Vaitkevicius VK (1979) The development of an acute intermittent schedule — Mitomycin-C. In: Carter SK, Crook ST, Alder NA (eds) Mitomycin-C. Current Status and New Developments. Academic Press, New York, London, pp 77–82

    Google Scholar 

  2. Burk K, Gropp C, De Riese W and Löbenau S (1985) Erfahrungen mit der Polychemotherapie MAF (Mitomycin C, Adriblastin, 5-Fluorouracil) beim progredienten metastasierten Prostatakarzinom. Helv Chir Acta 52:601–603

    Google Scholar 

  3. Carter SK (1979) Reflections and prospects. In: Carter SK, Crook ST, Alder NA (eds) Mitomycin-C. Current Status and New Developments. Academic Press, New York, London, pp 251–254

    Google Scholar 

  4. Crook ST (1979) Mitomycin-C: an overview. Ibid, In:, pp 1–4

    Google Scholar 

  5. Crook ST, Bradner WT (1976) Mitomycin-C: a review. Cancer Treat Rev 3:121–139

    Google Scholar 

  6. Eisenberger MA, Simon R, O'Dwyer PJ, Witten RE and Friedman MA (1985) A re-evaluation of non-hormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma. J Clin Oncol 3:827–841

    Google Scholar 

  7. Humphrey EW, Hymes AC, Ausman RK, Ferguson DJ (1961) An evaluation of actinomycin D and mitomycin C in patients with advanced cancer. Surgery 50:881–885

    Google Scholar 

  8. Jones BG, Fielding JW, Newman CE, Howell A, Brookes VS (1980) Intravascular haemolysis and renal impairment after blood transfusion in two patients on long term 5-Fluorouracil and Mitomycin-C. Lancet I:1275–1277

    Google Scholar 

  9. Jones WG, Fosså SD, Denis L, Coninx P, Glashan RW, Akdas A, De Pauw M (1983) An EORTC phase II study of vindesine in advanced prostate cancer. Eur J Cancer Clin Oncol 19:583–588

    Google Scholar 

  10. Jones WG and Members of the EORTC Genito-Urinary Cancer Co-operative Group (1984) EORTC phase II chemotherapy studies in prostate cancer. In: Denis L, Murphy GP, Prout GR, Schröder F (eds) Controlled Clinical Trials in Urologic Oncology. Raven Press, New York, pp 181–185

    Google Scholar 

  11. Kasimis BS, Miller JB, Kaneshiro CA, Forbes KA, Moran EM and Metter GE (1985) Cyclophosphamide versus 5-Fluorouracil, Doxorubicin and Mitomycin-C (FAM') in the treatment of hormone-resistant metastatic carcinoma of the prostate: A preliminary report of a randomised trial. J Clin Oncol 3:385–392

    Google Scholar 

  12. Kato T, Kumagai I, Nemoto R, Tamakawa Y, Harada M (1979) Intra-arterial use of microencapsulated Mitomycin C (MMC-mc) in the treatment of advanced prostatic cancer: a preliminary report. Proc Am Soc Clin Oncol: 408 (Abstr C-484)

  13. Logothetis CJ, Samuels ML, von Eschenbach AC, Trindade A, Ogden S, Grant C and Johnson DE (1983) Doxorubicin, Mitomycin-C, and 5-Fluorouracil (DMF) in the treatment of metastatic hormone refractory adenocarcinoma of the prostate, with a note on the staging of metastatic prostate cancer. J Clin Oncol 1:368–379

    Google Scholar 

  14. Martino S, Baker LH, Pollard RJ, Correa JJ, De Mattia MD (1979) Pulmonary toxicity of Mitomycin. In: Carter SK, Crook ST, Alder NA (eds) Mitomycin C. Current Status and New Developments. Academic Press, New York, London, pp 231–242

    Google Scholar 

  15. Pavone-Macaluso M (1971) Chemotherapy of vesical and prostatic tumours. Brit J Urol 43:701–708

    Google Scholar 

  16. Rabadi SJ, Khandekar JD, Miller HJ (1982) Mitomycin-induced haemolytic uraemic syndrome: case presentation and review of literature. Cancer Treat Rep 66:1244–1246

    Google Scholar 

  17. Ratanatharathorn V, Baker LH, Cadnapaphornchai P, Rosenberg BF, Vaitkevicius VK (1979) Clinical and pathologic study of Mitomycin C nephrotoxicity. In: Carter SK, Crook ST, Alder NA (eds) Mitomycin C. Current Status and New Developments. Academic Press, New York, London, pp 219–229

    Google Scholar 

  18. Smith PH (1981) Endocrine and cytotoxic therapy. In: Duncan W (ed) Recent Results in Cancer Research: Prostate Cancer, vol 78, Springer Berlin Heidelberg New York, pp 154–172

    Google Scholar 

  19. Whittington RW, Close HP (1970) Clinical experience with mitomycin C (NSC-269 80). Cancer Chemoth Rep 54:195–198

    Google Scholar 

  20. WHO Handbook for Reporting Results of Cancer Treatment (1979) World Health Orgahisation, Offset Publication No 48, Geneva

Download references

Author information

Author notes

  1. G. Stoter

    Present address: Rotterdam Cancer Institute, Groene Hilledijk 301, 3075 EA, Rotterdam, The Netherlands

Authors and Affiliations

  1. University Department of Radiotherapy, Cookridge Hospital, LS 16 6QB, Leeds, UK

    W. G. Jones

  2. Department of Medical Oncology and Radiotherapy, Norwegian Radium Hospital, 0310 Montebello, Oslo 3, Norway

    S. D. Fosså

  3. Department of Urology, Ospedale Di Circolo E Fondazione E S Macchi, Viale Borri, 57, 21100, Varese, Italy

    A. V. Bono

  4. Willem Alexander Ziekenhuis, Postbus 90152, 5200, MS 's-Hertogenbosch, The Netherlands

    J. J. Croles

  5. Department of Medical Oncology, Free University Hospital, De Boelelaan 1117, Postbus 7057, Amsterdam, The Netherlands

    G. Stoter

  6. EORTC Data Center, 125 Boulevard de Waterloo, 1000, Brussels, Belgium

    M. de Pauw & R. Sylvester

Authors
  1. W. G. Jones
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. D. Fosså
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. V. Bono
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J. J. Croles
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. G. Stoter
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M. de Pauw
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. R. Sylvester
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

members of the EORTC Genito-Urinary Tract Cancer Co-operative Group

Additional information

Other members of the EORTC Genito-Urinary Group contributing to this study were: J. G. M. Klijn, Rotterdam, The Netherlands; D. W. W. Newling, Hull, Great Britain; B. Richards, York, Great Britain, M. R. G. Robinson, Castleford, Great Britain

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jones, W.G., Fosså, S.D., Bono, A.V. et al. Mitomycin-C in the treatment of metastatic prostate cancer: report on an EORTC phase II study. World J Urol 4, 182–185 (1986). https://doi.org/10.1007/BF00327017

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00327017

Keywords

Search

Navigation